AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
Recent Articles
RELATED ARTICLES
-
Innogen Pharma jostles for a slice of the weight-loss market
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
AstraZeneca could face limited fallout from Chinese tax probe
AZN.US
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
